STOCK TITAN

Sera Prognostics, Inc. - SERA STOCK NEWS

Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.

Sera Prognostics, Inc. (SERA) delivers innovative diagnostic solutions for pregnancy complications through advanced biomarker technology. This news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones shaping maternal health diagnostics.

Access authoritative reporting on SERA's progress in precision medicine, including trial results for preterm birth prediction tests and collaborations with leading research institutions. Our curated news collection simplifies tracking of material events influencing the company's position in the $50B+ prenatal diagnostics market.

Key updates include FDA submissions for novel tests, peer-reviewed study publications, and commercial expansion initiatives. All content undergoes rigorous fact-checking to ensure compliance with financial disclosure standards while maintaining clinical accuracy.

Bookmark this page for real-time alerts on earnings announcements, intellectual property developments, and leadership changes. Stay informed about SERA's contributions to reducing neonatal complications through early intervention strategies validated by clinical evidence.

Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA) announced positive top-line results from the AVERT PRETERM TRIAL, showcasing significant improvements in neonatal health outcomes and reduced hospitalization duration. The study involved 1,453 expectant mothers and demonstrated statistically significant reductions in severe neonatal morbidity and mortality. Both primary outcomes were met, affirming the effectiveness of the PreTRM® test-and-treat strategy. These results build upon previous studies and support ongoing trials, including the large PRIME study. The PreTRM® Test provides crucial risk assessments for spontaneous preterm birth, aiming to enhance outcomes for mothers and infants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
73.28%
Tags
none
-
Rhea-AI Summary

Sera Prognostics (NASDAQ: SERA) partners with Fors Marsh to introduce the PreTRM® Test as part of employee maternity benefits, effective January 1, 2023. This innovative blood-based test provides early risk assessments for spontaneous preterm births, identifying nearly 90% of at-risk pregnancies. Fors Marsh aims to enhance workforce health and cut maternity costs through this offering. Sera asserts that the PreTRM® Test's predictive capabilities contribute significantly to improving maternal and neonatal health outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.63%
Tags
none
-
Rhea-AI Summary

Sera Prognostics Inc. (NASDAQ: SERA) published results from the ACCORDANT study, demonstrating the clinical utility and cost-effectiveness of its PreTRM® test. The study showed that enhanced care management for at-risk pregnant women could reduce neonatal and maternal hospital stays by 19% and 8.5%, respectively. Moreover, it predicted a 29% decrease in neonatal morbidity and mortality rates. These benefits were significant across diverse racial and ethnic groups. The findings highlight the potential of the PreTRM® test to address healthcare disparities in preterm birth, affecting over 10% of U.S. births annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
Rhea-AI Summary

Sera Prognostics Inc. (Nasdaq: SERA) reported third-quarter 2022 revenue of $87,000, up from $23,000 in Q3 2021. Total operating expenses increased to $11.3 million from $9.5 million year-over-year. R&D expenses rose to $4.2 million due to heightened laboratory and clinical study costs, while SG&A expenses slightly increased to $7.0 million. The net loss was $10.7 million, compared to $9.9 million in Q3 2021. The company holds approximately $111.2 million in cash and equivalents as of September 30, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.77%
Tags
-
Rhea-AI Summary

Sera Prognostics (Nasdaq: SERA) will report its third quarter fiscal year 2022 financial results on November 9, 2022, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the financial results and operational highlights. Sera is focused on improving maternal and neonatal health through its precision medicine PreTRM® test, which predicts preterm birth risk. The company aims to enhance clinical decision-making for high-risk pregnancies, addressing a significant healthcare issue with estimated annual costs in the U.S. of $25 billion related to preterm birth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
-
Rhea-AI Summary

Sera Prognostics, Inc. (NASDAQ: SERA) announces collaboration with Sonrava Health and Cerebrae to integrate its PreTRM® Test into Sonrava's employee maternity benefits. The PreTRM® Test, a clinically validated blood test, helps identify nearly 90% of pregnancies at risk for spontaneous preterm births, enabling proactive interventions. Through Cerebrae’s platform, value-based care strategies are evaluated, forecasting a positive ROI for Sonrava Health. This partnership aims to enhance maternal and neonatal health while promoting cost-effective healthcare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
none
Rhea-AI Summary

Sera Prognostics announced that its PreTRM® Test will be available to members of Banner – University Family Care. This test offers a unique, clinically validated method for assessing the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The partnership aims to enhance maternal and neonatal health while reducing healthcare costs. A prior economic analysis indicated that the PreTRM strategy could improve outcomes and lower treatment expenses compared to standard care. This collaboration reflects a shared commitment to innovative healthcare models.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary

Sera Prognostics Inc. (Nasdaq: SERA) reported its second quarter financial results for 2022, achieving a revenue of $78,000, up from $20,000 in Q2 2021. Operating expenses rose to $11.8 million, compared to $7.4 million in the previous year. The net loss for the quarter was $11.5 million, widening from $6.3 million a year ago. The company highlighted improved performance of the PreTRM test and contracts with new self-insured employer plans. As of June 30, 2022, cash and equivalents stood at approximately $121 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
-
Rhea-AI Summary

Sera Prognostics, focused on maternal and neonatal health, will release its second quarter fiscal year 2022 financial results on August 10, 2022, post-market. The conference call will start at 5:00 p.m. ET. Sera's PreTRM® Test helps predict preterm birth risks, addressing a significant health concern. The company aims to provide essential pregnancy biomarker information to healthcare providers to enhance patient outcomes and reduce healthcare costs. Additionally, it faces market risks that could impact its growth and revenue potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
Rhea-AI Summary

Sera Prognostics, Inc. (Nasdaq: SERA), a leader in maternal health diagnostics, will present at the 42nd Annual William Blair Growth Stock Conference on June 7, 2022, at 3:20 p.m. CT. CEO Gregory C. Critchfield will discuss the company's latest developments, including its innovative PreTRM® test, which predicts premature birth risk. The event will be available via live webcast on Sera's Investor website. Sera aims to improve healthcare outcomes for mothers and infants through precision medicine and has a significant pipeline focused on pregnancy-related complications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
conferences
Sera Prognostics, Inc.

Nasdaq:SERA

SERA Rankings

SERA Stock Data

128.06M
31.63M
13.84%
69.47%
2.45%
Medical Devices
Services-medical Laboratories
Link
United States
SALT LAKE CITY